Contribute Try STAT+ Today

In early May, a wing of Ohio State University’s Wexner Medical Center was eerily empty. The space had been cleared of patients as the pandemic raged. But it wasn’t going to waste.

Inside, a group of nurse practitioners were playing a game of digital tag. Lauren Chrzanowski, who has type 1 diabetes, was wearing a continuous glucose monitor, an implant with a transmitter that sends real-time glucose measurements to a dedicated receiver — when they’re close enough, anyway. On that day, she was trying to figure out just how far away her CGM could be from its receiver and still work.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.